Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review

Drug Safety

Volumn 25, Issue 4, 2002, Pages 233-250

  Gaynes, Bruce I ^a   Fiscella, Richard ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CIDOFOVIR; CORTICOSTEROID; CYTOCHROME P450; DICLOFENAC; FLUFENAMIC ACID; FLURBIPROFEN; GELATINASE B; GENTAMICIN; IBUPROFEN; INDOMETACIN; KETOROLAC TROMETAMOL; LEUKOTRIENE B4; MATRIX METALLOPROTEINASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ALLERGIC CONJUNCTIVITIS; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CATARACT; CONTACT DERMATITIS; CORNEA EPITHELIUM; CORNEA INJURY; CYTOTOXICITY; DRUG ABSORPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME ACTIVITY; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOXIA; INFLAMMATION; MAJOR CLINICAL STUDY; NONHUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0036264563     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225040-00002     Document Type: Review

References (99)

1. Lipid derived autocoids
2. Cyclo-oxygenase inhibitors in ophthalmology
3. Topical nonsteroidal drugs for ophthalmic use
4. In vivo effects of indomethacin and flurbiprofen on the locomotion of neutrophils elicited by immune and non-immune inflammation in the rat
5. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model
6. Outcome of specific COX-2 inhibition in rheumatoid arthritis
7. The discovery and function of COX-2
8. Caution recommended for prescribing and administering COX1/COX2 and COX2 specific NSAIDs
9. COX-1 and COX-2 tissue expression: Implications and predictions
10. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt
11. Disposition of topical flurbiprofen in normal and aphakic rabbit eyes
12. Ocular bioavailability and tissue distribution of ketorolac tromethamine in rabbits
13. Ocular and systemic bioavailability of ophthalmic flurbiprofen
14. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery
15. Double-masked, paired comparison clinical study of ketorolac tromethamine 0.5% eyedrops in the treatment of seasonal allergic conjunctivitis
16. Treatment of postoperative inflammation in ophthalmology
17. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery
18. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle controlled clinical trial
19. Analgesic efficacy and safety of ketorolac after photorefractive keratectomy
20. Topical diclofenac reduced pain following photorefractive keratectomy
21. Safety and efficacy of diclofenac ophthalmic in the treatment of corneal abrasions
22. Topical indomethacin solution versus dexamethasone solution for the treatment of inflammed pterygium and pinguecula: A prospective randomized clinical study
23. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin C
24. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivits
25. Exacerbation of asthma by topical diclofenac
26. Acute bronchial asthma associated with the administration of ophthalmic indomethacin
27. Acute asthma attack due to ophthalmic indomethacin
28. Mechanism of bronchospasm in aspirin-sensitive asthma
29. Severe asthma attacks precipitated by NSAIDs
30. Drug treatment of inflammation: Requirements and expectations
31. Gastric ulcer perforation associated with the use of injectable ketorolac
32. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout
33. Renal syndromes associated nonsteroidal antiinflammatory drugs
34. Drug-induced congenital defects: Strategies to reduce incidence
35. Antirheumatic medication during lactation
36. Consultation section
37. The incidence of atonic pupil following cataract surgery
38. Allergic contact dermatitis due to diclofenac and indomethacin
39. Decrease in normal human corneal sensitivity with topical diclofenac sodium
40. Voltaren associated with medication keratitis
41. The effects of the topical administration of non-steroidal anti-inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects
42. Persistent epithelial defect following penetrating keratoplasty: An adverse effect of diclofenac eyedrops
43. Lacrimal canalicular obstruction associated with topical ocular medication
44. Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery
45. Corneal melts associated with diclofenac after LASIK
46. Nonsteroidal anti-inflammatory drugs: Possible role in corneal ulcerations and perforations
47. Do NSAIDs cause wound melting following uncomplicated, small incision, scleral tunnel phacoemulsification
48. Peripheral corneal infiltrates following oral diclofenac administration
49. Corneal subepithelial infiltrates following excimer laser photorefractive keratectomy
50. Corneal complications associated with topical use of nonsteroidal anti-inflammatory drugs
51. Biotransformation in review: Applications in ocular disease and drug design
52. The effect of hypoxia on endogenous corneal epithelial eicosanoids
53. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy
54. Inflammation induced stimulation of the synthesis of prostaglandins and lipoxygenase-reactions produced in rabbit cornea
55. Cytochrome P450 and arachidonic acid metabolism in the corneal epithelium: Role in inflammation
56. Eicosanoid 12 (S)-HETE upregulates endothelial cell alpha V beta 3 integrin expression and promotes tumor cell adhesion to vascular endothelium
57. 12 (S)HETE is a mitogenic factor for microvascular endothelial cells: Its potential role in angiogenesis
58. Ocular cytochrome P-450 metabolism of arachidonate: Synthesis and bioassay
59. Inhibition of renal, cardiac and corneal Na+-K+ ATPase by 12 (R)hydroxyeicosatetraenoic acid
60. Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal derived eicosanoid
61. Oxidation and keto reduction of 12-hydroxy-5,8,10,14-eicosatetraenoic acids in bovine corneal epithelial microsomes
62. A closed eye-contact lens model of corneal inflammation, I: Induction of cytochrome P450 arachidonic acid metabolism
63. Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: Involvement of a cytochrome P-450B1 isoform
64. Induction of corneal endothelial cytochrome P450 arachidonate metabolism by contact lens wear
65. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium
66. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators
67. Induction of an acetaminophen sensitive cyclo-oxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
68. Inhibitors of arachidonic acid cascade in the management of ocular inflammation
69. Nonsteroidal anti-inflammatory drugs and cataract surgery
70. Detection of endogenous 12-hydroxyeicosatrienoic acid in human tear film
71. Essential ions for maintenance of the corneal epithelial surface
72. Improvement in corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor ONO-2235: A preliminary study
73. Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca?
74. Matrix metalloproteinases in epithelia from human recurrent erosion
75. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury
76. Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelantinase B) in rabbit articular chondrocytes
77. Possible roll of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting
78. Effect of non-steroidal anti-inflammatory drugs (NSAID) on the rabbit corneal epithelium studied by scanning electron microscopy
79. Diclofenac: The effect on the cornea with and without the epithelium
80. Topical non-steroidal agents and corneal wound healing
81. A study of topical nonsteroidal antiinflammatory drops and no pressure patching in the treatment of corneal abrasions
82. Effects of diclofenac eye drops on corneal epithelial structure and function after small incision cataract surgery
83. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclo-oygenases in chicken embryo fibroblasts
84. Keratitis, ulceration and perforation associated with topical nonsteroidal anti-inflammatory drugs
85. Fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution for inflammation after cataract surgery. A randomized, comparative, active treatment-controlled trial
86. Corneal penetration of diclofenac from a fixed combination of diclofenac-gentamicin eyedrops
87. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model
88. Irreversible corneal decompensation in patients treated with topical dorzolamide
89. Latanoprost and brimonidine: Therapeutic and physiologic assessment before and after non-steroidal anti-inflammatory therapy
90. Keratitis, ulceration and perforation associated with topical nonsteroidal anti-inflammatory drugs
91. Morphologic and physiologic effects of artificial tear formulations on corneal epithelial derived cells
92. Ultrastructural study of the conjunctiva in patients with keratoconjunctivitis sicca not associated with systemic disorders
93. New pieces for the puzzle: Nonsteroidal anti-inflammatory drugs and corneal ulcers
94. The pathology of dry eye: The interaction between ocular surface and the lacrimal glands
95. Topical diclofenac sodium decreases the substance P content of tears